title: Utilization of technologies to reduce allogeneic blood transfusion in the United States.
abstract: Concern over safety of the blood supply has led to the use of technologies to reduce allogeneic blood transfusion. The objective of this research was to determine the utilization of these technologies in the United States. We evaluated the following techniques: preoperative autologous donation (PAD), cell salvage (CS) and acute normovolemic haemodilution (ANH); and the following pharmaceuticals: aprotinin (APR), epsilon-aminocaproic acid (EACA), tranexamic acid (TXA), desmopressin (DDAVP) and recombinant human erythropoietin (EPO). In 1997, we conducted a cross-sectional mail survey of service chiefs at 1000 US hospitals randomly selected and stratified by status as a provider of open-heart surgery, geographical location and hospital bed size. Sixty-nine per cent (690) of hospitals responded to at least one of the four surveys sent to each hospital. Hospitals reported use of techniques more than pharmaceuticals (P < 0.001); PAD (83%, n = 206) and CS (82% n = 420) were used most frequently. Lack of familiarity was the most common reason cited for infrequent use of pharmaceuticals. Organizational characteristics (e.g. provision of open-heart surgery, size, geographical location, teaching status and type of hospital) were differentially associated with technology use. There is greater use of techniques than pharmaceuticals in US hospitals to reduce the need for allogeneic blood in the peri-operative setting. Providing open-heart surgery is strongly associated with the utilization of these technologies.
authors: Joint PhD Program in Public Policy, Georgia Institute of Technology and Georgia State University, Atlanta GA, USA. ablair@emory.edu
authors: A B
authors: AB
authors: Hutchinson
authors: D
authors: D
authors: Fergusson
authors: I D
authors: ID
authors: Graham
authors: A
authors: A
authors: Laupacis
authors: J
authors: J
authors: Herrin
authors: C D
authors: CD
authors: Hillyer
mesh_terms: D020811:Biomedical Technology; D001803:Blood Transfusion / Q000592:standards / Q000706:statistics & numerical data*; D001804:Blood Transfusion, Autologous / Q000706:statistics & numerical data; D006348:Cardiac Surgical Procedures; D019538:Health Care Surveys; D006438:Hemodilution / Q000706:statistics & numerical data; D006490:Hemostatics / Q000627:therapeutic use; D006742:Hospital Bed Capacity; D006761:Hospitals; D006801:Humans; D012044:Regression Analysis; D014184:Transplantation, Homologous / Q000706:statistics & numerical data*
chemical_list: D006490:Hemostatics